%20and%20TSR-022%20(combination)%20for%20Melanoma%20Stage%20III.png?md=1 "Dostarlimab (TSR-042) and TSR-022 (combination) for Melanoma Stage III Clinical Trial 2022 | Power")
Dostarlimab (TSR-042) and TSR-022 (combination) for Melanoma Stage III Clinical Trial 2022 | Power
g63792mmi006.gif
Frontiers | Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways | Nature Reviews Clinical Oncology
NIRAPARIB; TSR-042; TSR-022 3000-01-002
Current Oncology | Free Full-Text | New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer | HTML
New emerging targets in cancer immunotherapy: the role of TIM3 - ESMO Open
g63792mmi052.gif
![Top 10 Immunotherapy Clinical Trials [2022 Studies] | Power](https://pwr-og-img.withpower.com/Apply%20to%20this%20Phase%202%20clinical%20trial%20treating%20Hepatocellular%20Carcinoma,%20Carcinoma,%20Hepatocellular,%20Carcinoma:%0A%0ATremelimumab%20immunotherapy%20for%20Hepatocellular%20Carcinoma.png?md=1 "Top 10 Immunotherapy Clinical Trials [2022 Studies] | Power")
Top 10 Immunotherapy Clinical Trials [2022 Studies] | Power
What's Next for Immune Checkpoint Inhibitors: TIM-3?
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities | Nature Reviews Drug Discovery
Discovery of TSR-022, a novel, potent anti-TIM-3 therapeutic antibody
Discovery of TSR-022, a novel, potent anti-TIM-3 therapeutic antibody
TIM3 comes of age as an inhibitory receptor | Nature Reviews Immunology
Trials Listing
Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials - ScienceDirect
Tesaro, Inc. 2018 8-K Current report
Houssein A. Sater, MD on Twitter: "TsR-022 targets TIM-3 phase I trial results @sitcancer #SITC2017 https://t.co/E9RAIM3dUV" / Twitter
Discovery of TSR-022, a novel, potent anti-TIM-3 therapeutic antibody
g63792mmi059.gif
Cells | Free Full-Text | Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor | HTML
NIRAPARIB; TSR-042; TSR-022 3000-01-002
![PDF] TIM-3, a promising target for cancer immunotherapy | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fc28d57cc9f331c0747f1ccdb7504956bcbe7f2a/4-Table2-1.png "PDF] TIM-3, a promising target for cancer immunotherapy | Semantic Scholar")
PDF] TIM-3, a promising target for cancer immunotherapy | Semantic Scholar
Liver Cancer Pipeline Insight | Clinical Trial Research
